Business Context and Reporting Period
Company: Akari Therapeutics Plc (AKTX)
Filing Type: Form 8-K (Current Report)
Report Date: August 13, 2026
Reporting Period: First half of the year ending December 31, 2026 (H1 2026)
This filing serves as a notification that the Company issued a press release on August 13, 2026, announcing its financial results for the first half of 2026. The press release is attached as Exhibit 99.1 and incorporated by reference.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. The following metrics are not present in the source text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt Levels
- Liquidity Position
Note: Specific values for these metrics are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes in financial condition or operations compared to the prior comparable period. It only confirms the announcement of H1 2026 results.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release containing financial results but does not include the text of the commentary, guidance, or outlook.
Risks and Contingencies: No specific risks or contingencies are detailed in this cover sheet.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (the Press Release dated August 13, 2026) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical or operational milestones achieved in H1 2026 as detailed in the press release.
- Check for any updated guidance or forward-looking statements regarding the full year 2026 in the referenced exhibit.
- Confirm the status of the Interim Chief Financial Officer, Kameel Farag, and any implications for financial reporting continuity.